Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.
Bio-Techne (TECH.Q), together with Kantaro Biosciences, a commercial affiliate of Mount Sinai Health, announced today the expected release of their COVID-SeroIndex antibody kit. The SeroIndex
CytoSorbents (CTSO.Q) has been awarded a three-year contract valued at $4,421,487 to complete a preclinical development of the HemoDefend plasma and whole blood adsorber by
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy.
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should
Cognizant’s (CTSH.Q) shared investigator platform (SIP) has reached over 100,00 new users in 84 countries, according to a press release. The software as a service
Edwards Lifesciences Corporation (EW.NYSE) received U.S. Food and Drug Administration (FDA) approval for the KONECT RESILIA aortic valved conduit (AVC) today. The AVC is the
Technology is different from every other sector by virtue of one important factor – it scales. Because technology is scaleable, firms penetrate international markets easily,
Biotech companies especially those tackling Covid-19 are seeing incredible bumps on the boards with companies like Canadian Sona Nanotech (SONA.C), based out of Halifax, Nova
You know what grinds my gears? The fact that investors will happily speculate on Tesla (TSLA.NYSE) stock because they think they understand the automobile market, but won’t attempt to do the due diligence for biotechs because it’s “too hard”.
For part I of this series please click here. Cities across Canada are gradually returning to business as usual, and we’re winning the fight against
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto.
The history of humanity is the history of disease. We’ve mostly bumbled around from plague to plague, blind-sided and punch drunk by the ferocity of
3a-Diagnostics, a diagnostic partner for Xphyto Therapeutics (XPHY.C), confirmed the functionality of the peptide biosensors working in Xphyto’s oral dissolvable thin film (ODF) platform today.
Keynes once said that “the market can remain irrational longer than you can remain solvent”. Fundamentals departed market valuation long ago, but you could’ve at least expected market reaction to be in response to COVID-19 related news. Except it seems like that’s no longer the case.
This week’s digest of mushroom moves is a mixed bag of trash and glory, with the shrooms sector increasingly looking like the early days of the cannabis rush.
Small caps in Canada, especially in tech, are full of faux-companies. You know, the kind where the problem being solved isn’t really a problem, and
Our early coverage of Xphyto reveals the following company trait: Xphyto says, “We’re going to do this” – and then they do it – quickly.
BrainStorm Cell Therapeutics (BCLI.Q), a biotech company involved in a research study for amyotrophic lateral sclerosis (ALS), received a combined $500,000 grant from The ALS
Vektor is now proceeding with process implementation for the manufacture of Rotigotine patches for human clinical studies.
Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three reasons you think it’s great, and one thing you’ll openly admit they need to do better.” I got 35. Gulp.
Over the last couple of months, companies have found a way to muster up an effort to align their objectives with helping society recover from
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in
Here’s a simple and effective investment strategy: invest in companies that sell
products with growing inelastic demand.
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)
We’ve all seen it: the media craze about gluten and how it’s terrible for us. Except it generally lacks solid scientific consensus, and like most
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he
Mind Medicine (MMED.E) has worked together with University Hospital Basel’s Liechti Laboratory to discover and file and patent application in the United States for a
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.
Sona Nanotech (SONA.C) entered into service and supply agreements with a European-based contract organization to manufacture its COVID-19 rapid response virus detection test yesterday. The
Revive Therapeutics (RVV.C) intends to advance its product pipeline to human clinical studies in regions where its products have already acquired regulatory approval and are
“More than 4 million adults experience chronic daily migraine – with at least 15 migraine days per month,” states The Migraine Research Foundation, “It affects 39 million people in the U.S. and 1 billion worldwide.”
Tragedy and trying times brings out both the best and the worst in humanity. We have doctors and nurses risking their health and safety everyday
Regardless of how you might feel about it, the point remains: the flipside of any disaster is opportunity for those who know how and where
When a sector gets hot, small cap stocks can often get a bump by sidling up to the hot sector with a new product/idea/opportunity. When the dust clears, the intrinsic value of the new offering is typically deemed to be low. We saw it in 3D-printing, with Dung Beetle Treats. We saw it in weed with a $1 billion website that forgot to sell cannabis. We saw it in blockchain with a Cryptocoin for porno transactions.
Okay, so the world is burning, the Russians and Saudis are pouring low-cost fuel over it, the Americans are shocked that a reality TV show
We’ll take a wild guess that precisely NONE of the retail investors who just drove up the price of the MRNA would recognise a “stabilized form of S protein” if they met it on a beach, made sand castles with it – then took it home to play Spin-The-Bottle.
“A once-a-day pill that reduces HbA1c and improves time in range with continuous glucose monitoring, without increasing hypoglycemia or any signal for adverse events, is a big win for the future care of type 1 diabetes,” stated clinical researcher Dr. John Buse.
If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the
A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP.
Pregnancy is one of those things television makes look easy. Boy and girl both swipe appropriately on Tinder. They meet in a musty stairwell after
A Wuhan market price list offers 112 types of wild critters including peacocks, foxes, giant salamanders, snakes, rats, porcupines and camel meat.
Acceleron is finding solutions for serious and rare diseases. It has a pipeline of products moving towards commercialisation, including a co-promotion with the $152 billion Bristol-Myers Squibb (BMY.NYSE)
The first time we dealt with a coronavirus I was a lonely college student in Oshawa, Ontario and folks around me thought briefly that the
Haemonetics Corporation (HAE.NYSE) announced the purchase of a technology underlying the TEG6s Hemostasis Analyzer System from CoraMed Technologies, including the intellectual property they had licensed
Medical Marijuana (MJNA.OTC) announced today that their investment company AXIM Biotechnologies (AXIM.OTC) has signed a binding term sheet to acquire oncology research and development company
Eli Lilly and company (LLY.NYSE) and robotic cloud-computing provider, Strateos, unveiled the Lilly Life Sciences Studio lab, a new robotic laboratory in San Diego, Calfornia,
Abbott Laboratories (ABT.NYSE) received Food and Drug Administration (FDA) approval for a new alternative surgical technique for Abbott’s HeartMate 3 heart pump that would allow
With offices in 41 countries, 2.8 million members and a patriarchal structure, Greenpeace has global revenue of USD $300 million. Its most successful fundraising catalysts have been images of beautiful animals about to be slaughtered.
“Americans spend more on prescription drugs than anyone else in the world,” states Bloomberg, “It’s true that they take a lot of pills. But what
Amgen (AMGN.Q) signed a lease with BioMed Realty for a new 240,000 square foot Leadership in Energy and Environmental Design (LEED) candidate facility in the
Ever since the greasy arrogant squirrel-faced grin of Martin Shkreli turned our collective stomach, big pharma has come under fire for their pricing practices. Pharma
When markets closed Friday November 15, Karuna Therapeutics (KRTX.Q) was just another pharma-stock trading in the mid-teens trying to make drugs for patients with Alzheimer’s
Varian Medical Systems (VAR.NYSE) announced that the South Florida Proton Therapy Institute (SFPTI) has treated its first patient using the Varian ProBeam Compact single-room proton
Cognetivity Neurosciences (CGN.C) has reached the threshold of participants in their clinical evaluation study of its integrated cognitive assessment (ICA) platform for dementia sufferers to
The scene: Late 2005, a run down pharmacy in East Vancouver. It’s early on a Sunday morning, raining heavily outside, and I haven’t slept for
Psilocybin and other psychedelics are forcing their way out of prohibition as potentially viable treatments for not only depression and anxiety but also Alzheimer’s and
Here’s is a taste of the work we are doing over at shroomstocks.ca. Click here to read the full story! Yield Growth (BOSS.C) is all-in
My best friend growing up married a woman with severe rhinosinusitis and nasal polyps. That sounds about as serious as a case of the common
Cannabis has been good to us here at equity.guru. There are 1,283 pages of cannabis-related content on our site and it’s still growing. That said,
We all know someone who’s been touched by cancer. It’s been called the worst scourge of civilized mankind. It sweeps through a family, disrupting our
GW Pharmaceuticals (GWPH.Q) has received a recommendation from the European Medicines Agency (EMA) for the authorization of the company’s Epidyolex cannabis oral solution for use
Someone in the world develops dementia every three seconds. Alzheimer’s disease and other dementia-related disorders affect 50M people around the world and that number is
According to the World Health Organization, around 50 million people suffer from dementia worldwide and nearly 10 million new cases are diagnosed every year. Alzheimers
Buried in a news release discussing a shares-for-cash payment to an acquisition target, Emerald Health (EMH.V) stated Monday it is losing a board member over
World Class Extractions (PUMP.C), a newcomer in the extraction sector, signed an LOI to acquire Quadron Cannatech (QCC.C) today. This acquisition will put World Class
Cannabis went crazy in 2018. Billion-dollar acquisitions by international food and beverage giants like Constellation Brands (STZ.NYSE) as well as Canada and California’s legalization of recreational
What makes this cannabis market really exciting is that it’s largely uncharted territory. When cannabis went live last October, it opened the door for growers,
Titan Pharmaceuticals (TTNP.Q) is an American pharmaceutical company based out of San Francisco, California. The company has recently relaunched Probuphine, its six-month treatment for Opioid Use
Vitalhub (VHI.V) has come out strong in the first two weeks of 2019 showing a solid trajectory for the company’s direction in spite of a
by Guy Bennett Christmas Eve, 2018 – I’m writing this from a hospital bed in a hard scrabble town in the mountains of Yunnan Province,
If I was getting paid by the number of pitches I hear, I’d be making a lot more money than I do. Often, they’re terrible.
Sometimes when a public company is being quiet, the only way to figure out what they’re up to is to connect dots and assess risk. Stony
A few years back, I wrote about Helius Medical Technologies (HSM.T), which I heard about from Fabrice Taylor, and liked a lot as a long
I’ve noticed a subtle change in the order of things lately that, while it may seem a small thing, it’s actually a sign of something
Transitioning from a capital markets CEO to a pharma CEO is a smart move for a licensed cannabis producer about to rapidly expand its output,
Food safety is major concern for both producers and distributors, so it’s no surprise that the global food safety testing space is expected to be
I remember the first time BlueOcean NutraSciences (BOC.V) came to my boardroom. They were amped over something that, they were certain, was going to turn
You’ve got to give credit to Vinergy Resources (VIN.C), AKA MJ Biopharma, they said they were going to have plenty of news over the coming
